The FDA-authorized, saliva-based COVID-19 RT-PCR test expands testing access with a comfortable, at-home alternative – eliminating in-person waits and reducing exposure risk
DEERFIELD, Ill. and LENEXA, Kan., Feb. 24, 2021 /PRNewswire/ — Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., and Walgreens today announced that the FDA-authorized CRL Rapid Response COVID-19 Saliva Test is now available through Walgreens Find Care®, a digital health platform available on the Walgreens app and Walgreens.com. Sold under CRL’s HealthConfirm® brand, the COVID-19 Saliva Test is non-invasive and highly accurate, offering consumers the convenience of self-collecting the test right in their homes without supervision.
Self-Collected CRL Rapid Response™ Saliva Test is More Accurate Than Widely Used Anterior Nasal Swab Test and Key to the U.S. Safely Getting Back to Work
Highly Accurate CRL Rapid Response™ Saliva Test is Easy to Use, Competitively Priced; Delivers Results Right to Cell Phone
Strategic Partners Will Benefit from Complementary Strengths; Confirm BioSciences to Continue Operating Under Its Current Name
SAN DIEGO and LENEXA, Kan., Dec. 9, 2020 /PRNewswire/ — Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, announced today that the company has been acquired by Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S. Confirm will continue to operate as a subsidiary under its current name. The acquisition expands Confirm’s access to lab testing services and R&D capabilities, while CRL leverages Confirm’s massive customer base in Drugs of Abuse testing, large consumer-based retail contracts and current pipeline of COVID-19 testing products.
In the News
As Covid-19 Variants Invade, Testing Remains A Critical Line Of Defense
The pace of vaccine rollout is encouraging, but the war is not over—and companies still have a key role to play in preventing another debilitating surge.